促排卵治疗 中国就医指南

Ovulation induction (OI) is a cornerstone pharmacological intervention in reproductive medicine, designed to stimulate ovarian follicular development and trigger ovulation in individuals with anovulatory or oligo-ovulatory disorders—most commonly polycystic ovary syndrome (PCOS), hypothalamic amenorrhea, or unexplained infertility. Unlike natural cyclical ovulation regulated by the hypothalamic–pituitary–ovarian (HPO) axis, OI uses exogenous gonadotropin-releasing hormone (GnRH) analogues, clomiphene citrate, letrozole, or recombinant follicle-stimulating hormone (rFSH) to overcome endogenous hormonal dysregulation. Pathophysiologically, OI addresses impaired gonadotropin secretion (e.g., low FSH/LH pulsatility), ovarian resistance to gonadotropins (as in PCOS), or estrogen feedback abnormalities. It does not treat underlying causes but restores timely oocyte release—enabling timed intercourse or intrauterine insemination (IUI). Epidemiologically, anovulation accounts for ~25–30% of female infertility cases globally; in China, PCOS affects an estimated 5.6–10.4% of reproductive-age women, making OI one of the most frequently initiated fertility treatments in clinical practice. Key risk factors include obesity (BMI ≥28 kg/m²), insulin resistance, chronic stress, excessive exercise, and hyperprolactinemia. While generally safe, OI carries clinically relevant risks: ovarian hyperstimulation syndrome (OHSS) in 1–5% of cycles (higher with hCG trigger), multiple gestation (5–15% with clomiphene, up to 25% with gonadotropins), and rare thromboembolic events. Quality of life impact is multifaceted: patients often experience significant psychological burden—including anxiety, depression, and treatment-related fatigue—due to cycle monitoring demands (ultrasounds, blood draws), medication side effects (hot flashes, mood swings, bloating), financial strain, and uncertainty around conception success. Moreover, repeated unsuccessful cycles may erode self-efficacy and marital satisfaction. Importantly, OI is not indicated for tubal obstruction, severe male factor infertility, or premature ovarian insufficiency—where assisted reproductive technologies (ART) like IVF are more appropriate. Success rates vary: live birth per OI-IUI cycle ranges from 8–15% in PCOS patients using letrozole, declining with age >35 and longer infertility duration. Comprehensive care thus integrates endocrine evaluation, metabolic optimization (e.g., metformin, lifestyle counseling), and psychosocial support alongside pharmacotherapy.

# 促排卵治疗方案与费用明细（生殖医学科）

一、非手术/药物保守方案

适用人群：PCOS、下丘脑性闭经、轻度卵巢功能减退等无器质性病变者

• •克罗米芬方案：50–150 mg/日×5天，含基础B超监测（3–4次）、血清E₂/P/LH检测（4次）：2,800–4,200元
• •来曲唑方案（优选一线）：2.5–7.5 mg/日×5天，含动态卵泡监测+激素谱（6次B超+5项激素）：3,500–5,000元
• •Gn注射方案（尿促/重组FSH）：个体化剂量启动，含全程B超+血激素（8–10次监测+6–8项检验）：6,800–12,000元

二、微创介入方案

适用人群：药物抵抗型PCOS、多囊卵巢综合征伴高雄难控者

• •腹腔镜下卵巢打孔术（LOD）：单侧/双侧卵巢电凝打孔，含术前全套评估（AMH、胰岛素抵抗、心肺功能等）：18,500–23,000元（含术前检查费2,200元）

三、复杂/耐药/并发症方案

• •GnRH-a长方案联合微刺激（卵巢低反应者）：含垂体降调节+个体化促排+黄体支持强化：15,000–22,000元
• •拮抗剂方案+生长激素辅助（反复卵泡发育不良）：含GH注射及全程精细化监测：25,000–32,000元

方案快速选择指南

✅ 首次促排/预算≤5,000元 → 来曲唑方案 ✅ 药物抵抗/PCOS中重度 → Gn方案或LOD术（预算≥18,000元） ✅ 反复失败/卵巢储备低下 → 拮抗剂+GH强化方案（预算≥25,000元）